Sign In
Buy NURO
$4.58
+0 (+0%)
At Close: Jul 30, 2025
Why NeuroMetrix Shares Are Skyrocketing
10:56am, Thursday, 19'th May 2022
NeuroMetrix Inc (NASDAQ: NURO) shares are trading higher by 30.10% at $4.06 after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation device as an aid f
NeuroMetrix, Inc. (NURO) CEO Shai Gozani on Q1 2022 Results - Earnings Call Transcript
10:58am, Tuesday, 26'th Apr 2022
NeuroMetrix, Inc. (NASDAQ:NURO ) Q1 2022 Earnings Conference Call April 26, 2022 8:00 AM ET Company Participants Thomas Higgins - Senior Vice President and Chief Financial Officer Shai Gozani - Presid
NeuroMetrix, Inc. Announces Date for First Quarter 2022 Financial Results Conference Call
09:00am, Tuesday, 19'th Apr 2022
WOBURN, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 first quarter financial results before the opening of the market on A
NeuroMetrix''s Quell Neuromodulator Will Be Tested In Long COVID-19 Syndrome
07:21pm, Thursday, 24'th Feb 2022 Benzinga
NeuroMetrix Inc''s (NASDAQ: NURO ) Quell wearable neuromodulation technology will be evaluated for fibromyalgia-like syndrome in individuals with post-acute COVID-19 syndrome (PACS, or "long COVID"). Quell is an advanced, non-invasive neuromodulation technology covered by 22 U.S. utility patents and numerous … Full story available on Benzinga.com
NeuroMetrix, Inc.''s (NURO) CEO Dr. Shai Gozani on Q4 2021 Results - Earnings Call Transcript
02:04pm, Thursday, 27'th Jan 2022 Seeking Alpha
NeuroMetrix reports Q4 results (NASDAQ:NURO)
12:06pm, Thursday, 27'th Jan 2022 Seeking Alpha
NeuroMetrix press release (NURO): Q4 net loss of $1MRevenue of $1.82M (+0.6% Y/Y).
NeuroMetrix, Inc.'s (NURO) CEO Dr. Shai Gozani on Q4 2021 Results - Earnings Call Transcript
09:04am, Thursday, 27'th Jan 2022
NeuroMetrix, Inc.'s (NURO) CEO Dr. Shai Gozani on Q4 2021 Results - Earnings Call Transcript
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2021 Financial Results Conference Call
12:10pm, Thursday, 20'th Jan 2022
WOBURN, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 fourth quarter and full year financial results before the opening of t
NURO Stock: Why NeuroMetrix Investors Are Feeling No Pain Today
04:54pm, Tuesday, 18'th Jan 2022 InvestorPlace
NeuroMetrix (NURO) stock is rocketing higher on Tuesday thanks to the FDA granting it Breakthrough Designation for one of its devices.
NeuroMetrix surges on FDA Breakthrough Designation for neurostimulation technology
04:06pm, Tuesday, 18'th Jan 2022 Seeking Alpha
Nano-cap, NeuroMetrix <> is trading sharply higher in morning hours after announcing that the FDA granted the Breakthrough Designation for its Quell technology designed to…
NeuroMetrix, Mainz lead healthcare gainers; Dyne, Allarity among losers
03:09pm, Tuesday, 18'th Jan 2022 Seeking Alpha
NeuroMetrix (NURO) +39%. Mainz Biomed MYNZ +26%. Dyne Therapeutics DYN -17%. Allarity Therapeutics (ALLR) -15%.
Neurometrix up 35% after receiving FDA Breakthrough Designation for its Quell tech
01:52pm, Tuesday, 18'th Jan 2022
NeuroMetrix Inc. (NASDAQ: NURO) shot up 35% after announcing that the FDA awarded it Breakthrough Device Designation for its Quell technology. This innovative technology is designed to help reduce se
Market Update: Why Are Stocks Down Tuesday?
01:21pm, Tuesday, 18'th Jan 2022
It's time for a market update and we're diving into why stocks are down on Tuesday and there's plenty of reasons for today's dip. The post Market Update: Why Are Stocks Down Tuesday?
NURO Stock: Why NeuroMetrix Investors Are Feeling No Pain Today
11:54am, Tuesday, 18'th Jan 2022
NeuroMetrix (NURO) stock is rocketing higher on Tuesday thanks to the FDA granting it Breakthrough Designation for one of its devices. The post NURO Stock: Why NeuroMetrix Investors Are Feeling No Pai
NeuroMetrix Shares Rally On FDA Breakthrough Tag For Neurostimulation Device
10:35am, Tuesday, 18'th Jan 2022
The FDA has granted Breakthrough Designation to NeuroMetrix Inc's (NASDAQ:NURO) Quell technology for reducing moderate to severe symptoms of chemotherapy-induced peripheral neuropathy (CIPN) that
